You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics and clinical covariates

From: The role of whole brain radiation therapy in the management of melanoma brain metastases

  Median (IQR) Range
Age at stereotactic radiosurgery (years) 60 (51 – 68) 28 – 92
Time from primary Melanoma to Brain Metastasis (months) 39 (17 – 69) 0 – 347
Diameter of largest brain Metasasis (mm) 11 (8 – 21) 3 – 55
  n (%)
Gender:
  Male 99 (67%)
Female 48 (33%)
Extent of extracranial metastases:*
  0   12 (8%)  
1 Limited 28 (19%) 86 (59%)
2   46 (31%)  
3   35 (24%)  
4 Extensive 18 (12%) 61 (41%)
5   7 (5%)  
6   1 (1%)  
Extracranial disease status:
  Absent 12 (8%)
Present and stable 23 (16%)
Present and progressive 112 (76%)
Number of brain metastases:
  1 59 (40%)
2 – 3 53 (36%)
> 3 (4–10) 35 (24%)
Karnofsky performance status:
  50 – 60 6 (4%)
70 – 80 61 (41%)
90 – 100 80 (54%)
Initial treatment:
   DF/BWCC BIDMC
SRS Alone 29 (43%) 66 (84%)
SRS + WBRT 23 (34%) 0 (0%)
SRS + Surgery 2 (3%) 11 (14%)
SRS + Surgery + WBRT 14 (21%) 2 (3%)
Whole-brain radiation therapy:
   DF/BWCC BIDMC
Up-Front (with SRS) 37 (54%) 2 (3%)
As Salvage Therapy 9 (13%) 24 (30%)
Never 22 (32%) 53 (67%)
Systemic treatment with SRS:
  None 78 (53%)
Temozolomide 41 (28%)
Other 28 (19%)
Melanoma-GPA score:
  0 – 1 23 (16%)
2 41 (28%)
3 44 (30%)
4 39 (27%)
  1. Abbreviations: IQR interquartile range, DF/BWCC Dana-Farber/Brigham & Women’s Cancer Center, BIDMC Beth Israel Deaconess Medical Center, SRS stereotactic radiosurgery, WBRT whole brain radiation therapy, Melanoma-GPA melanoma-specific Graded Prognostic Assessment for brain metastases.
  2. *To define the “extent of extracranial metastases”, each patient was assigned a number between 0 and 6 based on evidence of melanoma metastases to the following 6 sites: liver, lung, adrenal glands, other visceral organs, bone, or other distant site (e.g. lymph nodes or subcutaneous tissue). The median number of extracranial body sites affected by metastatic melanoma is 2. “Limited extracranial metastases” was defined as ≤ 2 extracranial body sites affected by metastatic melanoma. “Extensive extracranial metastases” was defined as ≥ 3 extracranial body sites affected by metastatic melanoma.
  3. Systemic Treatment with SRS = systemic treatment given after SRS and before disease progression.